Teijin Pharma Signs Gout Drug Marketing Rights Deal With Astellas Taiwan
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma of Japan May 12 signed a marketing agreement with Astellas Taiwan, a subsidiary of Astellas Pharmaceutical, which grants excusive marketing rights for gout durg Uloric (febuxostat) to Astellas in Taiwan. Positioned as one of Teijin's global products, febuxostat obtained approvals in Europe in April 2008. After obtaining U.S.FDA approval in February, it was marketed jointly with Takeda Pharmaceutical starting in March. In Asia, the drug is under review by Korea FDA. Taiwan has a high gout prevalence compared to other Asian countries. (Click here for more - Japanese language